NRAS Q61R is the most common NRAS hotspot in melanoma (~20% of cutaneous melanomas). Bini...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NRAS-Q61R-MELANOMA |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MELANOMA |
| Sources | SRC-CIVIC SRC-ESMO-MELANOMA-2024 SRC-NCCN-MELANOMA-2025 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | NRAS Q61R |
| Disease | DIS-MELANOMA |
| ESCAT tier | IB |
| Recommended combinations | nivolumab + ipilimumab (1L preferred), binimetinib (NEMO; investigational/off-label) |
| Evidence summary | NRAS Q61R is the most common NRAS hotspot in melanoma (~20% of cutaneous melanomas). Binimetinib (MEKi) monotherapy improved PFS vs dacarbazine in NEMO (Dummer et al. Lancet Oncol 2017) — modest benefit; not FDA-approved as monotherapy. ICI (anti-PD1 ± anti-CTLA4) is the standard 1L for NRAS-mut metastatic melanoma. MEKi+CDK4/6i combos under investigation. |
Notes
ESCAT IB. Under BIO-RAS-MUTATION (no dedicated BIO-NRAS-Q61R yet — flag for BIO authoring).
Used By
No reverse references found in the YAML corpus.